Clinical Orthopaedics and Related Research®

, Volume 470, Issue 8, pp 2295–2301 | Cite as

Bisphosphonate-associated Femur Fractures Have High Complication Rates with Operative Fixation

  • Mark L. Prasarn
  • Jaimo Ahn
  • David L. Helfet
  • Joseph M. Lane
  • Dean G. Lorich
Clinical Research



Bisphosphonate-associated femur fractures have been well described but the preoperative patient factors, treatment modalities, and complications of treatment are unclear.


We asked whether a diagnosis of osteoporosis, the characteristic radiographic features of bisphosphonate-related femur fractures, and complication rates differed in patients with operatively treated femoral shaft fractures receiving bisphosphonates and in patients not receiving bisphosphonates.


We retrospectively reviewed 43 patients with bisphosphonate-associated femoral shaft fractures (including subtrochanteric) from 2002 to 2008 and 20 patients with similar fractures but not treated with bisphosphonates. Similar implants were used in both groups, but a greater number of adjuvants were used in the bisphosphonate cohort. We recorded preoperative osteoporosis and radiographic findings of the characteristic bisphosphonate femur fracture and early complications. The minimum followup was 5 months (mean, 29 months; range 5–60 months).


Preoperatively a greater percentage of patients treated with bisphosphonates had confirmed osteoporosis than those not treated with bisphosphonates (24% versus 5%, respectively), a greater percentage had a proximal fracture location (48% versus 40%, respectively), and their mean cortex to shaft diameter ratio was greater (24% versus 15%, respectively). The bisphosphonate cohort had a higher rate of intraoperative fractures (21% versus 0%) and postoperative plate failures (30% versus 0%).


Despite low rates of other risk factors and ample use of biologic adjuvants, patients treated with bisphosphonates having femur fractures have more complications.

Level of Evidence

Level III, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.


Bisphosphonate Alendronate Femur Fracture Teriparatide Femoral Shaft 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We thank Omesh Paul MD, Paul Matuszewski MD, and Craig Klinger BS for assistance in formulating patient cohorts and thoughtful discussion regarding the manuscript.


  1. 1.
    Ahn JK, Lee J, Cha HS, Koh EM. Non-traumatic fracture of the femoral shaft in a patient taking long-term bisphosphonate therapy. Rheumatol Int. 2011;31:973–975.PubMedCrossRefGoogle Scholar
  2. 2.
    Aspenberg P. Bisphosphonate-induced fractures: nature strikes back? Acta Orthop. 2008;79:459–460.PubMedCrossRefGoogle Scholar
  3. 3.
    Cao Y, Mori S, Mashiba T, Westmore MS, Ma L, Sato M, Akiuama T, Shi L, Komatsubara S, Miyamato K, Norimatsu H. Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res. 2002;17:2237–2246.PubMedCrossRefGoogle Scholar
  4. 4.
    Capeci CM, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am. 2009;91:2556–2561.PubMedCrossRefGoogle Scholar
  5. 5.
    Cermak K, Shumelinsky F, Alexiou J, Gebhart MJ. Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy. Clin Orthop Relat Res. 2010;468:1991–1996.PubMedCrossRefGoogle Scholar
  6. 6.
    Chrischilles EA, Dasbach EJ, Rubenstein LM, Cook JR, Tabor HK, Black DM and for the Fracture Intervention Trial Research Group. The effect of alendronate on fracture-related healthcare utilization and costs: The Fracture Intervention Trial. Osteoporos Int. 2001;12:654–660.PubMedCrossRefGoogle Scholar
  7. 7.
    Das De S, Setiobudi T, Shen L, Das De S. A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg Br. 2010;92:679–686.CrossRefGoogle Scholar
  8. 8.
    Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci. 1999;96:133–138.PubMedCrossRefGoogle Scholar
  9. 9.
    Goh S-K, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007;89:349–353.PubMedCrossRefGoogle Scholar
  10. 10.
    Gomberg SJ, Wustrack RL, Napoli N, Arnaud CD, Black DM. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab. 2011;96:1627–1632.PubMedCrossRefGoogle Scholar
  11. 11.
    Ha YC, Cho MR, Park KH, Kim SY, Koo KH. Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy? Clin Orthop Relat Res. 2010;468:3393–3398.PubMedCrossRefGoogle Scholar
  12. 12.
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MD, Axelrod DW, Miller PD. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344–1352.PubMedCrossRefGoogle Scholar
  13. 13.
    Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med. 1998;338:485–492.PubMedCrossRefGoogle Scholar
  14. 14.
    Isaacs JD, Shidiak L, Harris IA, Szomor ZL. Femoral insufficiency fractures associated with prolonged bisphosphonate therapy. Clin Orthop Relat Res. 2010;468:3384–3392.PubMedCrossRefGoogle Scholar
  15. 15.
    Karpf DB, Shapiro DR, Seeman E, Ensrud KE, Johnston CC Jr, Adami S, Harris ST, Santora AC 2nd, Hirsch LJ, Oppenheimer L, Thompson D. Prevention of nonvertebral fractures by alendronate: a meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA. 1997;277:1159–1164.PubMedCrossRefGoogle Scholar
  16. 16.
    Koh JS, Goh SK, Png MA, Kwek EB, Howe TS. Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture? J Orthop Trauma. 2010;24:75–81.PubMedCrossRefGoogle Scholar
  17. 17.
    Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008;39:224–231.PubMedCrossRefGoogle Scholar
  18. 18.
    Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008;358:1304–1306.PubMedCrossRefGoogle Scholar
  19. 19.
    Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, van der Meulen MC, Lorich DG, Lane JM. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporosis Int. 2009;20:1353–1362.CrossRefGoogle Scholar
  20. 20.
    Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995;333:1437–1443.PubMedCrossRefGoogle Scholar
  21. 21.
    Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13:581–589.PubMedCrossRefGoogle Scholar
  22. 22.
    Mashiba T, Hui S, Turner CH, Mori S, Johnston CC, Burr DB. Bone remodeling at the iliac crest can predict the changes in remodeling dynamics, microdamage accumulation, and mechanical properties in the lumbar vertebrae of dogs. Calcif Tissue Int. 2005;77:180–185.PubMedCrossRefGoogle Scholar
  23. 23.
    Mashiba T, Mori S, Burr DB, Komatsubara S, Cao Y, Manabe T, Norimatsu H. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab. 2005;23(suppl):36–42.PubMedCrossRefGoogle Scholar
  24. 24.
    Napoli N, Novack D, Armamento-Villareal R. Bisphosphonate-associated femoral fracture: implications for management in patients with malignancies. Osteoporos Int. 2010;21:705–708.PubMedCrossRefGoogle Scholar
  25. 25.
    Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22:346–350.PubMedCrossRefGoogle Scholar
  26. 26.
    Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294–1301.PubMedCrossRefGoogle Scholar
  27. 27.
    Ott SM. Atraumatic bilateral femur fracture in long-term bisphosphonate use. Comment on Orthopedics. 2009 Aug;32(8). pii: = 41933. doi: 10.3928/01477447-20090624-27. Orthopedics. 2010;33:468.
  28. 28.
    Riggs BL, Melton LJ III. The prevention and treatment of osteoporosis. N Engl J Med. 1992;327:620–627.PubMedCrossRefGoogle Scholar
  29. 29.
    Sayed-Noor AS, Sjoden GO. Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy: a case report. Acta Orthop. 2008;79:565–567.PubMedCrossRefGoogle Scholar
  30. 30.
    Sayed-Noor AS, Sjoden GO. Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res. 2009;467:1921–1926.PubMedCrossRefGoogle Scholar
  31. 31.
    Somford MP, Geurts GF, den Teuling JW, Thomassen BJ, Draijer WF. Long-term alendronate use not without consequences? Int J Rheumatol. 2009;2009:253432.PubMedGoogle Scholar
  32. 32.
    Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;CD001155.Google Scholar

Copyright information

© The Association of Bone and Joint Surgeons® 2012

Authors and Affiliations

  • Mark L. Prasarn
    • 1
    • 2
    • 3
  • Jaimo Ahn
    • 1
    • 2
    • 3
  • David L. Helfet
    • 1
    • 2
    • 3
  • Joseph M. Lane
    • 1
    • 2
    • 3
  • Dean G. Lorich
    • 1
    • 2
    • 3
  1. 1.Orthopedic Trauma ServiceHospital for Special SurgeryNew YorkUSA
  2. 2.New York Presbyterian HospitalNew YorkUSA
  3. 3.Weill Medical College of Cornell UniversityNew YorkUSA

Personalised recommendations